<DOC>
	<DOCNO>NCT01466153</DOCNO>
	<brief_summary>The overall purpose study determine MEDI-551 , use combination salvage chemotherapy ( bendamustine ) patient relapse refractory CLL eligible Autologous Stem Cell Transplant ( ASCT ) , superior efficacy compare rituximab population .</brief_summary>
	<brief_title>A Phase 2 , Multicenter , Open-label Study MEDI-551 Adults With Relapsed Refractory Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm Bcell Chronic Lymphocytic Leukemia ( CLL ) accord National Cancer Institute criterion ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 ; Adequate hematological function Any chemotherapy , radiotherapy , immunotherapy , biologic , investigational , hormonal therapy treatment lymphoma within 28 day prior treatment ; Exposure bendamustine within 180 day study enrollment Prior autologous allogeneic stem cell transplantation ( SCT ) ; Clinically significant abnormality electrocardiogram ( ECG ) determine treat physician medical monitor ; History invasive malignancy within 5 year except localized/in situ carcinoma ; Evidence active infection , Confirmed current central nervous system involvement leukemia lymphoma ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic lymphocytic leukemia ; leukemia ; B-Cell malignancy ; anti-CD19 ; monoclonal antibody ; CLL ; Refractory ; Relapse ; Non-Hodgkin 's Lymphoma</keyword>
</DOC>